BIESF
Price:
$32
Market Cap:
$1.40B
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune a...[Read more]
Industry
Biotechnology
IPO Date
2014-01-09
Stock Exchange
OTC
Ticker
BIESF
According to Biotest AG’s latest financial reports and current stock price. The company's current ROE is 4.98%. This represents a change of 300.06% compared to the average of 1.24% of the last 4 quarters.
The mean historical ROE of Biotest AG over the last ten years is 0.02%. The current 4.98% ROE has changed 31.01% with respect to the historical average. Over the past ten years (40 quarters), BIESF's ROE was at its highest in in the June 2018 quarter at 31.84%. The ROE was at its lowest in in the September 2015 quarter at -21.55%.
Average
0.02%
Median
-4.06%
Minimum
-20.01%
Maximum
36.71%
Discovering the peaks and valleys of Biotest AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 621.49%
Maximum Annual ROE = 36.71%
Minimum Annual Increase = -3745.54%
Minimum Annual ROE = -20.01%
Year | ROE | Change |
---|---|---|
2024 | 4.97% | -80.46% |
2023 | 25.46% | -398.95% |
2022 | -8.52% | -48.83% |
2021 | -16.64% | 134.03% |
2020 | -7.11% | 621.49% |
2019 | -0.99% | -102.68% |
2018 | 36.71% | -3745.54% |
2017 | -1.01% | -92.07% |
2016 | -12.70% | -36.52% |
2015 | -20.01% | -600.47% |
The current ROE of Biotest AG (BIESF) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
7.31%
5-year avg
-0.37%
10-year avg
0.02%
Biotest AG’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Biotest AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Biotest AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Biotest AG's ROE?
How is the ROE calculated for Biotest AG (BIESF)?
What is the highest ROE for Biotest AG (BIESF)?
What is the 3-year average ROE for Biotest AG (BIESF)?
What is the 5-year average ROE for Biotest AG (BIESF)?
How does the current ROE for Biotest AG (BIESF) compare to its historical average?